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Research
Perfluorinated chemicals (PFCs) have a broad 
range of applications in the manufacture of 
various industrial and commercial products, 
such as fluoro  polymers, surfactants, emul­
sifiers, and non  stick coatings. PFCs have 
been of considerable scientific and public 
concern because some of them are environ­
mentally persistent, bio  accumula  tive, and 
widely detected in humans, wildlife, and the 
environ  ment (Giesy and Kannan 2001; Olsen 
et al. 2007).
Because of environmental concerns, the 
3M company voluntarily phased out electro­
chemical fluorination­based fluoro  chemicals 
in 2001 (Dupont 2005). Consequently, 
the current production of fluorinated poly­
mers and surfactant is mostly based on 
telomerization processes (Lehmler 2005). 
Polyfluorinated iodine alkanes (PFIs) are 
organic iodides composed of a fluorinated 
carbon backbone terminated by iodine substi­
tution (Table 1) and are important interme­
diates in the synthesis of various fluorinated 
chemicals (Brace 1999; Prevedouros et al. 
2006). In the telomerization process, PFIs 
are used to synthesize fluoro  telomer alcohols 
(FTOHs) and other related PFCs. In turn, 
FTOHs are intermediates in the production 
of surfactants and fluoro  polymers, and these 
volatile compounds have been detected in 
the atmosphere around the world (Ellis et al. 
2004). The annual production of FTOHs 
increased to 11–13 × 103 metric tons in 
2002 (Ellis et al. 2003). The annual world 
production of PFIs has been estimated to 
exceed 4,000 metric tons (Organisation for 
Economic Co­operation and Development 
2004), and the increasing demand of fluoro­
telomer products might increase the risk of 
emission of volatile PFIs to the environment 
(Ruan et al. 2010a, 2010b). Fluorinated 
iodine alkanes (FIAs) and fluorinated telomer 
iodides (FTIs) have been detected in air and 
soil samples around a fluoro  chemical manu­
facturing plant in Shandong province in 
northern China (Ruan et al. 2010a). Residual 
FIAs and FTIs could also be incorporated 
into FTOH containing raw materials and 
fluoro  telomer­based products during manu­
facturing. 1­Iodoperfluoro  octane (PFOI) and 
6:2 FTI have been detected in fluoro  telomer 
raw materials and selected fluoro  telomer­
based products, such as urethane polymer 
and phosphate surfactant (Larsen et al. 2006). 
Furthermore, unreacted residual FTOH has 
also been found in commercial and industrial 
products and could be released to the ambient 
environment as well (Dinglasan­Panlilio and 
Mabury 2006; Larsen et al. 2006). Likewise, 
residual PFIs in fluorinated polymers and 
surfactants can be released into the environ­
ment and degrade to other persistent PFCs. 
Abiotic or biotic transformation of FTIs 
could contribute to the environmental bur­
den of FTOHs and perfluoro  carboxylic acids 
(PFCAs) (Young et al. 2008). There is there­
fore a potential risk for release of PFIs to the 
environment due to direct emission during 
manufacturing and indirect emission from 
some fluorinated products.
Increasing evidence has shown that some 
PFCs may have endocrine­disrupting potency. 
Some PFCs can disturb the thyroid system 
and neuro  endocrine function, activate both 
peroxisome proliferator­activated receptors and 
estrogen receptors (ERs), and induce develop­
mental toxicity in rodents (Lau et al. 2004). 
The estrogenic effects of some PFCs have been 
studied in many aspects. For example, Maras 
et al. (2006) demon  strated the estrogen­like 
properties of FTOHs in MCF­7 cells. Using 
yeast two­hybrid assays, Ishibashi et al. (2007, 
2008) demonstrated that FTOHs can activate 
the male medaka (Oryzias latipes) and human 
ER. Liu et al. (2007) reported that vitello­
genin expression was induced by perfluoro­
octane sulfonate (PFOS), perfluoro  octanoic 
acid (PFOA), and FTOHs in primary cultured 
tilapia hepato  cytes, and they suggested that 
estrogenic effects may be mediated through 
the ER pathway. FTOHs also induced vitello­
genin in male medaka fish through the activa­
tion of ER, whereas PFOS and PFOA did not 
(Ishibashi et al. 2008).
Little information is currently available 
regarding the estrogenic effects of PFIs. In 
the present study, we used three in vitro bio­
assays—E­screen assay, MVLN assay, and 
evaluation of an estrogen­responsive gene—to 
comprehensively evaluate the estrogenic 
potencies of PFIs. The structural features 
responsible for estrogenic effects were identi­
fied by the alternations in potency derived 
from specific structural changes.
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Ba c k g r o u n d: Polyfluorinated iodine alkanes (PFIs) are important intermediates in the synthesis 
of organic fluoride products. Recently, PFIs have been detected in fluoropolymers as residual raw 
materials, as well as in the ambient environment. 
oBjectives: High production volumes and potential environmental releases of PFIs might become 
a concern, but the exposure risk and toxicity of these chemicals are still unclear. In this study, we 
investigated the potential estrogenic effects of PFIs.
Me t h o d s : We studied the estrogenic effects of fluorinated iodine alkanes (FIAs), fluorinated 
telomer iodides (FTIs), and fluorinated diiodine alkanes (FDIAs) using the E-screen and MVLN 
assays and the evaluation of estrogen-responsive genes in MCF-7 cells.
re s u l t s: FIAs have an iodine atom at one end of the perfluorinated carbon chain. 1-Iodoperfluoro-
hexane (PFHxI) and 1-iodoperfluoro  octane (PFOI) promoted the proliferation of MCF-7 cells, 
induced luciferase activity in MVLN cells, and up-regulated the expression of TFF1 and EGR3. In 
these assays, other FIAs gave negative responses. FDIAs have an iodine atom at each end of the per-
fluorinated carbon chain, and all the FDIAs showed estrogenic effects. The estrogenic potencies of 
FIAs and FDIAs correlate well with the carbon chain length of the chemicals. The optimum chain 
length for estrogenic effects is six carbons, and then eight and four carbons. All FTIs have a single 
iodine atom at the end of a partially fluorinated carbon chain. None of the FTIs showed estrogenic 
effects in the tests.
co n c l u s i o n s: The estrogenic effects of PFIs are dependent on the structural features of iodine 
substitution and chain length. This research will be helpful in further understanding the estrogenic 
effects of perfluorinated compounds.
key w o r d s : endocrine disruptor, estrogenic effects, in vitro assay, perfluorinated chemicals, 
poly  fluorinated iodine alkanes. Environ Health Perspect 120:119–125 (2012).  http://dx.doi.
org/10.1289/ehp.1103773 [Online 11 October 2011]Wang et al.
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Materials and Methods
Chemicals. The chemical structures of 
tested compounds are shown in Table 1. 
We purchased 1­iodoperfluoro  butane 
(PFBI; 98% pure), 1­iodoperfluoro  hexane 
(PFHxI; 99% pure), 1­iodoperfluoro­
decane (PFDI; 97% pure), 1­iodoperfluoro­
dodecane (PFDoI; 97% pure), 6:2 FTI 
(96% pure), 8:2 FTI (96% pure), hexadeca­
fluoro­1,8­diiodooctane (PFODI; 98% pure), 
1H­perfluorooctane (PFOC; 99% pure), 
1­bromo  perfluoro  octane (PFOB; 99% pure), 
1­iodohexane (98% pure), and 4­hydroxy­
tamoxifen (OHT; 98% pure) from Sigma 
Chemical Company (St. Louis, MO, USA); 
PFOI (98% pure), 4:2 FTI (95% pure), 10:2 
FTI (95% pure), and PFOA (98% pure) 
from Fluka (Buchs, Switzerland); and octa­
fluoro­1,4­diiodobutane (PFBDI; 97% pure), 
dodecafluoro­1,6­diiodohexane (PFHxDI; 
97% pure), and 17β­estradiol (E2; 99% pure) 
from Alfa Aesar (Ward Hill, MA, USA). We 
dissolved all the PFIs, PFOB, E2, and 1­iodo­
hexane in ethanol. PFOA and PFOC were 
dissolved in dimethyl sulfoxide as 100 mM 
and 10 mM stock solutions. All stock solu­
tions were stored at –20°C.
Cell culture. Human MCF­7BUS breast 
adeno  carcinoma cells and MVLN cells 
were cultured in 100­mm culture dishes 
in a humidified atmosphere of 5% CO2 at 
37°C. Cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM)/F­12 
(Hyclone, Logan, UT, USA) containing 10% 
fetal bovine serum, 100 U/mL streptomycin­
penicillin, 2 mM l­glutamine, and 1% insu­
lin­transferrin­selenium supplement (all from 
Gibco, Grand Island, NY, USA).
E-screen  assay.  MCF­7BUS  cells 
were kindly provided by A.M. Soto and 
C. Sonnenschein (Tufts University School of 
Medicine, Boston, MA, USA). In response 
to ERα agonists, the mitotic effect leads to 
the proliferation of MCF­7BUS cells. We 
performed the E­screen assay following a 
method modified from the protocol by Soto 
et al. (1995). Cells were trypsinized and 
plated into the interior 60 wells of 96­well 
plates at the density of 3,000 cells/well. 
Before each experiment, cells were starved 
in steroid­free (SF) medium for 48 hr to 
minimize the basal hormonal activity during 
assays. SF medium consisted of phenol red–
free DMEM/F­12 (Hyclone) supplemented 
with 5% dextran­charcoal­treated fetal bovine 
serum (Hyclone), 100 U/mL streptomycin­
penicillin, and 2 mM l­glutamine. Cells were 
treated with serial dilutions of test chemi­
cals (from 1 nM to 100 μM) in SF medium; 
a concentration range of 0.01–200 pM E2 
was used as the positive control. We used a 
WST­1 proliferation kit (Roche Diagnostics, 
Mannheim, Germany) to assess proliferation 
after 6 days of exposure according to the kit 
instructions. The WST­1 assay is based on 
the enzymatic cleavage of the tetrazolium salt 
WST­1 to formazan by cellular mitochon­
drial dehydrogenases present in viable cells. 
The absorbance of the WST­1 solution was 
detected by a microplate reader (Varioskan 
Flash, Thermo Fisher Scientific, Waltham, 
MA, USA) at 450 nm, with the reference 
wave length at 690 nm. The cell prolifera  tion 
effect was calculated from the solvent con­
trol (0.1% ethanol)­corrected absorbance and 
expressed as the percentage of maximal absor­
bance of the positive control. Three replicates 
were used in each experiment.
MVLN assay. The MVLN cell line was 
kindly provided by J.P. Giesy (Michigan State 
University, East Lansing, MI, USA). This cell 
line was stably transfected with the luciferase 
reporter gene and estrogen­responsive ele­
ment derived from the Xenopus vitellogenin 
A2 gene. ER agonists can induce the pro­
duction of luciferase in MVLN cells (Pons 
et al. 1990). Cells were seeded in the inte­
rior 60 wells of a 96­well ViewPlate (Packard 
Instrument Company, Boston, MA, USA) 
at a density of 7 × 104 cells/well, starved in 
SF medium for 48 hr, and exposed to test 
compounds for 2 days. A concentration range 
of 0.5 pM–1 nM E2 was used as a positive 
control, whereas the exposure concentration 
range of test chemicals was 0.1–100 μM. 
Luciferase activity was measured with the 
LucLite kit (Packard Instruments) according 
to the manufacturer’s protocol. We meas  ured 
luminescence by microplate reader (Varioskan 
Flash) and integrated the luminescence signal 
for 10 sec. Total protein content was meas­
ured by the Bradford assay (Tiangen, Beijing, 
China) to normalize luminescent units. The 
results are given as relative luminescent unit 
per microgram protein. The maximal induc­
tion of positive control (corrected for sol­
vent control, 0.1–0.2% ethanol) was set as 
100%, and the responses of other chemicals 
were converted to a percentage of the maxi­
mum level. Three replicates were used in each 
experi  ment. The cytotoxicity of tested chemi­
cals was examined by WST­1 kit in parallel 
and routinely observed under microscope to 
identify the exposure concentration range.
RNA isolation and reverse transcrip-
tion polymerase chain reaction (RT-PCR). 
MCF­7BUS cells were seeded in six­well 
plates at the density of 1.0 × 106 cells per well, 
starved in SF medium for 48 hr, and exposed 
to test compounds for 48 hr. First, cells were 
rinsed twice with cold phosphate­buffered 
saline, and total RNA was isolated using Trizol 
reagent (Invitrogen Inc., Carlsbad, CA, USA) 
following the manufacturer’s protocol. The 
260 nm and 280 nm absorbance reading of 
total RNA was performed using a Nanodrop 
spectrophotometer (Thermo Scientific, 
Waltham, MA, USA). The concentration of 
Table 1. The structures of tested chemicals.
Structure Chemical
Fluorinated iodine alkanes (FIAs)
IC F2(CF2)aCF3
F F PFBI, 1-iodoperfluorobutane (a = 1)
PFHxI, 1-iodoperfluorohexane (a = 3)
PFOI, 1-iodoperfluorooctane (a = 5)
PFDI, 1-iodoperfluorodecane (a = 7)
PFDoI, 1-iodoperfluorododecane (a = 9)
Fluorinated telomer iodides (FTIs)
CF2(CF2)bCF3
I 4:2 FTI, 1H,1H,2H,2H-perfluorohexyl iodide (b = 2)
6:2 FTI, 1H,1H,2H,2H-perfluorooctyl iodide (b = 4)
8:2 FTI, 1H,1H,2H,2H-perfluorodecyl iodide (b = 6)
10:2 FTI, 1H,1H,2H,2H-perfluorododecyl iodide (b = 8)
Fluorinated diiodine alkanes (FDIAs)
I
F
I
F c
PFBDI, Octafluoro-1,4-diiodobutane (c = 4)
PFHxDI, Dodecafluoro-1,6-diiodohexane (c = 6)
PFODI, Hexadecafluoro-1,8-diiodooctane (c = 8)
F
F
F
F
F F
F F
F F
F
F
F F F
F
R
F
PFOC, 1H-perfluorooctane (R = H)
PFOB, 1-bromoperfluorooctane (R = Br)
F
F
F
F
F F
F F
F F
F
F
F FF
O
HO
PFOA, perfluorooctanoic acid
I 1-Iodohexane
a, b, and c indicate the number of CF2 units.Polyfluorinated iodine alkanes exhibit estrogenic effects in vitro
Environmental Health Perspectives  •  v o l u m e  120 | n u m b e r 1 | January 2012  121
RNA was quantified by the reading at 260 nm. 
The 260:280 nm ratios were between 1.8 and 
2.0, which indicates that the extracted RNA 
was sufficiently pure. 
We used a two­step quantitative RT­PCR 
to quantify gene expression. Total RNA was 
converted to cDNA using M­MLV (Moloney 
murine leukemia virus) reverse transcriptase 
(Promega, Madison, WI, USA) with oligo 
dT(15), following the manufacturer’s instruc­
tions. The final cDNA solution was diluted five 
times with DNase/RNase­free water (Gibco). 
Quantitative PCR was performed with a 
Stratagene MX3005 thermal cycler (Stratagene, 
La Jolla, CA, USA). PCR reaction mixtures 
(25 μL) contained 12.5 μL GoTaq Green 
Master Mix (Promega), 2 μL diluted cDNA, 
and 0.2 μM sense/antisense primers. The ther­
mal cycle was 5 min at 95°C, followed by 45 
cycles of 15 sec at 95°C, 30 sec at 55°C, and 
30 sec at 72°C. The primer sequences of early 
growth response protein 3 (EGR3) were derived 
from Terasaka et al. (2004). We designed the 
primers of internal gene β‑actin and trefoil fac­
tor 1 (TFF1; pS2) with Primer Premier 5 soft­
ware (Premier Biosoft International, Palo Alto, 
CA, USA). The primer sequences were as fol­
lows: for β‑actin (NM_001101), 5´­CACTCT 
TCCAGCCT  TCCTTCC­3´ (forward) and 
5´­AGGTCTTTGCG  GATGTCCAC­3´ 
(reverse);  for  EGR3  (NM_004430), 
5´­CCATGAT  TC  CTGACTACAACCTC­3´ 
(forward)  and  5´­GTGGA  TCTGCT 
TGTCTT  TGAATG­3´ (reverse); and for 
TFF1  (NM_003225),  5´­AGAAGCG 
TGTCTGAGGTGTC­3´ (forward) and 
5´­GCAAATAAG  GGCTGCTGTT­3´ 
(reverse). The quantification of target gene 
expression was based on a comparative cycle 
threshold (Ct) value. We normalized the 
expression level of each target gene to its refer­
ence gene β‑actin. The fold change of the tar­
get genes was analyzed by the 2−ΔΔCt method 
(Livak and Schmittgen 2001). We used melt­
ing curve analysis and agarose gel electrophore­
sis to verify the correct PCR products.
Statistical analysis. All results are expressed 
as the mean ± SD. For statistical analysis, we 
used one­way analysis of variance (ANOVA) 
and Tukey’s multiple range test to assess the 
significance of mean differences. Difference 
was considered significant at a p­value ≤ 0.05. 
The concentration–response analyses were 
performed with four­parameter logistic curve 
regression analysis according to the following 
formula: 
y = minimum + (maximum – minimum) 
  ÷ [1 + (x/EC50)Hill slope],  [1]
where y is the response value, x is the log con­
centration of the test compound, and EC50 is 
the concentration that induces half of the maxi­
mum proliferation effect or luciferase activity.
EC50 values were calculated from this 
non  linear regression model. EC20 were   
calculated as 
 ECx = [x/(100 – x)](1/Hill slope) × EC50,  [2]
where x is 20% of the maximum effects, and 
the Hill slope and EC50 were calculated from 
Equation 1.
All statistical analyses were performed 
using Sigma Plot (version 10.0; Systat Software 
Inc., San Jose, CA, USA).
Results
Stimulation of MCF-7 cell proliferation. 
We used the E­screen assay to investi­
gate the estrogenic activities of 12 PFIs in 
MCF­7 cells. FIAs are mono  iodized fluori­
nated alkanes with even­numbered chains 
that have 4–12 carbons. PFBI [4 carbons 
in its alkyl chain (C­4)], PFDI (C­10), and 
PFDoI (C­12) did not show proliferation 
effects within the concentration ranges, 
whereas PFHxI (C­6) and PFOI (C­8) pro­
duced full concentration–response curves 
compared with E2 (Figure 1A); EC50 values 
were 0.63 μM and 1.15 μM for PFHxI and 
PFOI, respectively (Table 2). The prolifera­
tion effects appeared to be dependent on the 
chain lengths of FIAs. Fluorinated diiodine 
alkanes (FDIAs) have even­numbered chains 
with 4 to 8 carbons. All FDIAs produced full 
concentration–response curves in the E­screen 
assay (Figure 1B). The relative proliferation 
effects were in the following order: PFHxDI 
(C­6) > PFODI (C­8) > PFBDI (C­4). 
Likewise, prolifera  tion potency also seems 
to be related to the specific carbon chain 
length of FDIAs. The EC50 values of PFBDI 
(1.45 μM), PFHxDI (7.5 nM), and PFODI 
(43.3 nM) were much lower than those of 
the corresponding FIAs with the same chain 
length. The order of their relative proliferation 
potencies was PFHxDI > PFODI > PFHxI 
Figure 1. Concentration–response proliferation effects of FIAs (A) and FDIAs (B) in the E-screen assay. The 
relative proliferation effects are expressed as mean ± SD of triplicate measurements in one representative 
experiment.
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Concentration (M) Concentration (M)
E2
PFBI
PFHxI
PFOI
PFDI
PFDoI
E2
PFBDI
PFHxDI
PFODI
Table 2. Maximum induction and effective concentrations of tested chemicals based on the E-screen and 
MVLN assays.
E-screen MVLN assay
Compound
Maximum 
induction (%)a EC50
Relative 
potencyb
Maximum 
induction (%)c  EC50 EC20
Relative 
potencyb 
E2 100 3.12 pM 1 100 16.4 pM 4.14 pM 1
PFBI NDd — — NDe — — —
PFHxI 99 0.63 μM 4.9 × 10–6 47 26.7 μM 14.1 μM 0.29 × 10–6
PFOI 101 1.15 μM 2.7 × 10–6 25 35.1 μM 20.4 μM 0.2 × 10–6
PFDI NDd — — NDe — — —
PFDoI NDd — — NDe — — —
4:2 FTI NDd — — NDe — — —
6:2 FTI NDd — — NDe — — —
8:2 FTI NDd — — NDe — — —
10:2 FTI NDd — — NDe — — —
PFBDI 97 1.45 μM 2.2 × 10–6 21 29.6 μM 13.8 μM 0.3 × 10–6
PFHxDI 100 7.5 nM 4.2 × 10–4 73 1.13 μM 0.38 μM 1.1 × 10–5
PFODI 105 43.3 nM 7.2 × 10–5 38 2.87 μM 1.07 μM 3.8 × 10–6
PFOA NDd — — NDe — — —
PFOC NDd — — NDe — — —
PFOB NDd — — NDe — — —
1-Iodohexane NDd — — NDe — — —
ND, not detected. 
aPercentage of the maximum proliferation effects of tested compounds to that of E2. bRatio of EC50 of E2 to that of test 
compounds. cPercentage of the maximum induction effects of tested compounds to that of E2. dThe maximum rela-
tive proliferation effect was < 7%; the absorbance ratio of E2 (100 pM) to control was 2.1 ± 0.2. eThe maximum relative 
luciferase activity was < 5%; the relative luminescent unit ratio of E2 (1 nM) to control was 13.5 ± 2.4. Wang et al.
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> PFOI > PFBDI. These compounds are thus 
considered to behave like xeno  estrogens in the 
E­screen assay.
Transactivation in MVLN cells. The 
MVLN assay has been widely used to study 
ER activity of test compounds (Freyberger 
and Schmuck 2005). In the present study, 
we used the MVLN assay to further inves­
tigate ER activity and estrogenic potency of 
PFIs. Before the MVLN assay, we tested the 
cytotoxic effects of each compound using the 
WST­1 assay. Exposure of MVLN cells to 
FIAs, FTIs, or FDIAs did not produce sig­
nificant cyto  toxicity within the concentra­
tion ranges, and no cytotoxic effects were 
observed by microscopic examination (data 
not shown).
Because these compounds did not show 
maximum induction compared with E2, rela­
tive potency based on the EC20 would be 
more reliable than that derived from the EC50 
(Villeneuve et al. 2000). The estrogenic effects 
of PFIs revealed by the MVLN assay were in 
accordance with the results of the E­screen 
assay. As shown in Figure 2A, the induction 
of luciferase activity by PFBI, PFDI, and 
PFDoI were at the basal level (< 5%), 
whereas PFHxI and PFOI induced luciferase 
activity in a dose­related manner. PFHxI 
(EC20 = 14.1 μM) showed higher estrogenic 
activity than did PFOI (EC20 = 20.4 μM) in 
MVLN cells, with maximum induction val­
ues of 47% and 25%, respectively (Table 2). 
Luciferase activity induced by FDIAs seems to 
be related to the specific carbon chain length 
(Figure 2B). PFHxDI (EC20 = 0.38 μM) 
showed stronger estrogenic potency than 
did PFODI (EC20 = 1.07 μM) and PFBDI 
(EC20 = 13.8 μM), with the maximum induc­
tion values of 73%, 38%, and 21%, respec­
tively. Because the difference of EC50 or EC20 
values among PFHxI, PFOI, and PFBDI 
were small, we compared the estrogenic 
potency with the maximum induction value 
in an MVLN assay. The order of estrogenic 
potency was PFHxDI > PFHxI > PFODI 
> PFOI > PFBDI, which is comparable to 
results from the E­screen assay. Similarly, 
FDIAs possessed stronger estrogenic potency 
than did FIAs in the MVLN assay (PFBDI 
> PFBI; PFHxDI > PFHxI; PFODI > PFOI), 
which indicated that iodine substitution at 
the end of a fluorinated chain may enhance 
the estrogenic potency of FIAs. The optimum 
chain length for estrogenic activity was six 
carbons for FIAs and for FDIAs in both of 
these   estrogen­screening assays. 
Comparison of PFCs with similar struc-
tures. FTIs are partially fluorinated alkyl 
iodides, which are produced by the ethylation 
of FIAs in telomerization processes. Compared 
with FIAs and FDIAs, FTIs with various chain 
lengths did not show estrogenic effects in the 
E­screen or MVLN assays within the tested 
concentration ranges (0.01–200 μM). We used 
a nonfluorinated hydrocarbon, 1­iodo  hexane 
(C­6), as the control to study the effects of 
fluorination on estrogenic effects. Three eight­ 
carbon PFCs—PFOA, PFOC, and PFOB—
that contain no iodine substitution on the car­
bon chain were used as compari  sons to study 
the effects of iodine substitution on estrogenic 
effects. As we suspected, 1­iodohexane, PFOA, 
PFOC, and PFOB showed negative results 
in the estrogen­screening assays (Table 2). 
These results further emphasize that a perfluo­
rinated alkyl chain and iodine substitution are 
important structural features for the estrogenic 
effects of PFIs.
Coexposure assay with OHT in MVLN 
assay. We used OHT, a strong estrogen 
antago  nist in the mammary gland, to block the 
ER in the MVLN assay. OHT was co  exposed 
with PFHxI, PFOI, PFBDI, PFHxDI, or 
PFODI. We used the highest induction con­
centrations obtained from MVLN assay in the 
coexposure experi  ments and the gene expres­
sion assay. As shown in Figure 3, co  exposure 
of OHT with the tested chemicals resulted in 
marked reduction of luciferase activity, which 
further confirmed that these xenoestrogens 
can activate the ER.
Expression of estrogen-responsive genes. 
After MCF­7 cells were exposed to a series of 
PFCs for 48 hr, the expression levels of two 
estrogen­responsive genes (EGR3 and TFF1) 
were analyzed by real­time PCR. The TFF1 
gene is involved in cell proliferation and also 
serves as a biomarker gene responding to 
estrogens (Brown et al. 1984; Jorgensen et al. 
2000). As one of the ER­mediated estrogen­
inducing genes, EGR3 belongs to the early 
growth response family and plays an impor­
tant role in the estrogen­dependent induc­
tion of the immune evasion system (Inoue 
et al. 2004). The expression levels of EGR3 
and TFF1 are up­regulated by natural and 
synthetic estrogens in MCF­7 cells (Terasaka 
et al. 2004). PFHxI, PFOI, PFBDI, PFHxDI, 
and PFODI, which showed estrogenic effects 
in the E­screen and MVLN assays, signifi­
cantly up­regulated the estrogen­responsive 
genes by 4.4­, 2.7­, 2.7­, 5.7­, 8.5­, and 
7.7­fold for TFF1 and by 2.4­, 3.6­, 2.4­, 
Figure 2. Concentration–response luciferase activity of FIAs (A) and FDIAs (B) in the MVLN assay. The 
relative luciferase activities are expressed as mean ± SD of triplicate measurements in one representative 
experiment.
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Figure 3. Coexposure effects of the tested chemicals with OHT in the MVLN assay. The ER antagonist OHT 
(10 nM) was coexposed with 1 nM E2, 100 μM PFHxI, 100 μM PFOI, 100 μM PFBDI, 20 μM PFHxDI, or 40 μM 
PFODI. The relative luciferase activities are expressed as the mean ± SD of triplicate measurements in one 
representative experiment.
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9.1­, and 11.2­fold for EGR3 (Figure 4A). 
PFOC, PFOB, 1­iodohexane, PFBI, PFDI, 
PFDoI, and FTIs did not affect the expres­
sion of EGR3 or TFF1, but PFOA slightly 
up­regulated TFF1 by 1.57­fold. The levels 
of EGR3 and TFF1 mRNA were greatly ele­
vated by 8.7­ and 9.2­fold upon exposure 
to E2 (Figure 4B). Therefore, PFHxI, PFOI, 
PFBDI, PFHxDI, and PFODI showed estro­
genic activity in these assays. These xeno­
estrogens activated ER, which was followed 
by increased expression of the estrogen­ 
responsive genes. PFBDI showed weaker 
estrogenic potency than did PFHxDI or 
PFODI in the E­screen and MVLN assays, 
whereas the expression of EGR3 and TFF1 
induced by PFHxDI and PFODI was much 
higher than that induced by PFBDI. The 
up­regulation of EGR3 and TFF1 was also 
greater for FDIAs compared with the mono­
iodized FIAs. This adds further evidence that 
an increase in iodine substitution at the end 
of the fluorinated chain can enhance the 
estrogenic   potencies of FIAs.
Discussion
The endocrine­disrupting effects elicited by 
industrial chemicals have been of extensive 
concern (Colborn et al. 1993). Exposure to 
xeno  estrogens may lower sperm count and 
male fertility and increase the incidence of 
breast and testicular cancer in humans 
(Toppari et al. 1996). Most of the adverse 
effects of these compounds are thought to be 
mediated through ER activation. Although 
the environmental behaviors of PFIs are not 
known, these volatile and high­production­
volume chemicals could be released into the 
ambient environment during production, 
storage, and transport. The atmospheric oxi­
dation of PFIs may contribute to the increased 
levels of other PFCs in the environment. 
Studies of the potential toxicities of PFIs are 
therefore needed for health risk evaluation. 
In this study, we investigated the estrogenic 
effects of PFIs by the E­screen and MVLN 
assays and the expression of estrogen­respon­
sive genes. Our results showed that PFHxI, 
PFOI, PFBDI, PFHxDI, and PFODI exert 
estrogenic effects through activation of the 
ER. The relative estrogenic potencies obtained 
from the E­screen and MVLN assays are both 
related to the specific carbon chain length of 
FIAs and FDIAs. The optimum chain length 
for estrogenic effects is six carbons, and iodine 
substitution on the perfluorinated chain was 
crucial for the estrogenic effects. Those potent 
compounds were able to fully stimulate cell 
proliferation of MCF­7 cells, but this was not 
the case for the induction of reporter gene 
expression in MVLN cells. This discrepancy 
might be due to the difference of initial seed­
ing density, exposure time, and sensitivity 
between the two assays. The expression of the 
estrogen­responsive gene by these PFIs further 
confirmed the results. The estrogenic poten­
cies of FDIAs were higher than that of the 
FIAs, indicating that the increasing number 
of iodine substitutions on FIAs renders the 
chemical more potent in inducing estrogenic 
activity. PFHxDI (C­6), with two iodine 
substitutions (one at each end) of the per­
fluorinated chain, showed the highest potency 
among the PFIs. 
Considerable evidence has indicated that 
chain length determines the biological effect 
of PFCs (Hu et al. 2002; Liao et al. 2009; 
Upham et al. 1998). Bioconcentration and 
bioaccumulation of PFCs are related to the 
length of the fluorinated chain in different 
species (Martin et al. 2003). Cytotoxic end 
points of PFCs such as in vitro cytotoxic 
effects, the alteration of cell membrane poten­
tial, and cytosolic pH are directly related to 
perfluorinated chain length (Kleszczynski and 
Skladanowski 2009). The inhibition of per­
fluorinated fatty acids on gap junction inter­
cellular communication also depends on chain 
length; shorter PFCs, including perfluoro­
butane  sulfonate and perfluoro  hexane  sulfonate, 
did not show effects, whereas PFOS signifi­
cantly inhibits gap junction inter  cellular com­
munication (Hu et al. 2002; Upham et al. 
1998). The interference of PFCs on cultured 
rat hippocampal neurons was also related 
to the carbon chain length and functional 
groups (Liao et al. 2009). Our findings sug­
gest that FDIAs and some of the FIAs exert 
estrogen effects through the activation of ER. 
Because the solubility of non  polar FIAs in 
culture media decreased with increasing chain 
length, the lack of estrogenic effects for PFDI 
and PFDoI might be attributed, in part, to 
decreased solubility and bioavailability of 
long­chain FIAs.
We used the non  fluorinated organic 
iodide 1­iodohexane to study the effect of 
fluori  na  tion on estrogenic effects compared 
with PFHxI. In the screening assays, 1­iodo­
hexane did not exert estrogenic effects, indi­
cating that fluorination is an important 
structural feature for estrogenic activity. The 
hydrophobic property of the fluorinated 
chain imparts the proteino  philic and lipo­
philic property of PFCs and results in the 
inter  action of PFCs with multiple biological 
molecular targets in various species. PFOA 
did not show proliferation effects in MCF­7 
cells, as previously reported by Maras et al. 
(2006). In the present study, we found that 
PFOA, PFOB, and PFOC also lack estrogenic 
effects. By comparing the structure–activity 
relationship between these PFCs, we propose 
that the iodine substitution is a key attribute 
for the estrogenic effect. The estrogenic effect 
was also lower for mono  iodized fluorinated 
alkanes than for diiodized fluorinated alkanes, 
which further supports our assumption.
FTOHs exert estrogenic activity in MCF­7 
cells and aquatic organisms (Ishibashi et al. 
2008; Maras et al. 2006). FTOHs behave as 
estrogens because of the similarity of their 
chemical structure and properties to other 
xeno  estrogens, such as 4­nonyl  phenol. In the 
telomerization processes, fluoro  telomer iodides 
Figure 4. Effects of tested chemicals on mRNA expression of estrogen-responsive genes TFF1 (pS2) and EGR3 in MCF-7 cells. (A) Cells exposed to 0.1% ethanol 
(control), 50 μM PFBI, 50 μM PFHxI, 50 μM PFOI, 40 μM PFDI, 40 μM PFDoI, 50 μM PFBDI, 20 μM PFHxDI, 40 μM PFODI, or 100 pM E2 for 48 hr. (B) Cells exposed 
to 0.1% ethanol, 50 μM PFOA, 50 μM PFOC, 50 μM PFOB, 50 μM 1-iodohexane, 50 μM 4:2 FTI, 50 μM 6:2 FTI, 40 μM 8:2 FTI, 40 μM 10:2 FTI, or 100 pM E2 for 48 hr. 
Results are expressed as the mean ± SD of triplicate measurements in one representative experiment. 
*p < 0.05, and **p < 0.01, compared with the control. ANOVA and Tukey’s multiple range test were used to assess the significance of mean differences.
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are oxidized to produce FTOHs. Compared 
with FTOHs, none of the FTIs induced 
cell proliferation, which indicated that the 
hydroxyl group is more important for the 
estrogenic effects than is iodine substitution 
in partially fluorinated chemicals. Some of the 
PFIs activated the ER and induced luciferase 
activity in MVLN cells. However, it is ques­
tionable whether these PFIs are able to directly 
bind to and activate the ER. Structural fea­
tures such as a phenol ring and a hydrophobic 
group attached para to the hydroxyl group are 
essential for the estrogenic effects (Blair et al. 
2000; Laws et al. 2006; Suzuki and Shapiro 
2007). Furthermore, hydroxylated analogs 
of poly  brominated diphenyl ethers and poly­
chlorinated biphenyls have been shown to 
exert estrogenic effects (Bergeron et al. 1994; 
Fielden et al. 1997; Meerts et al. 2001). 
Therefore, it may be reasonable to expect that 
hydroxylated forms of FIAs and FDIAs could 
also be estrogenic.
Compared with PFOI, both PFOB and 
PFOC showed no estrogenic activity. It is 
likely that bond strength also determines their 
reactivity. The strength of the bonds is C–F 
(467 kJ/mol) > C–H (453 kJ/mol) > C–Br 
(290 kJ/mol) > C–I (228 kJ/mol). Among 
the four halogens, fluorine is the most electro­
negative and iodine the least. The polariza­
tion of the C–I bond is lower than that of 
the C–H bond and the other carbon–halogen   
bonds. Because iodine is a good leaving atom 
and because of the chemical reactivity of 
the C–I bond, it would be easier for PFIs to 
be converted to their hydroxylated analogs 
during the exposure studies. Oxidation of 
FIAs can result in the formation of PFCAs 
(Lehmler 2005). In this reaction, CnF2n+1OH 
is thought to have been formed by the cleav­
age of C–I bonds in FIAs and addition of OH 
(Yamamoto et al. 2007). We hypothesize that 
CnF2n+1I is hydrolyzed to CnF2n+1OH in the 
culture media or inside the cells, and the deg­
radation products or the metabolites of PFIs 
are the possible targets for ER, thereby exert­
ing estrogenic activity. However, the under­
lying mechanisms for the estrogenic effects of 
PFIs have not been completely clarified, and 
further studies are also warranted to charac­
terize possible catabolites of PFIs, which 
might also exhibit estrogenic activity.
The main functions of hormones are to 
maintain homeo  stasis and regulate reproduc­
tion and development. Exposure to endocrine­
disrupting chemicals may cause adverse effects 
to the organs and glands that secrete hormones, 
further resulting in endocrine toxicity such as 
impaired reproduction and develop  ment. PFIs 
are volatile chemicals and have been detected 
around fluoro  chemical manufacturing areas 
(Ruan et al. 2010a). As important precursors 
for the synthesis of organic fluoride products, 
PFIs could be incorporated into fluoro  telomer 
raw materials and   fluorotelomer­based products 
as residues (Larsen et al. 2006). Occupational 
and indoor environments might be exposure 
risk zones, and inhalation could be a possible 
exposure route.
Conclusion
Some PFIs could act on ERs and potentially 
cause detrimental effects on reproductive 
and develop  mental systems. To our knowl­
edge, this is the first study to find estrogenic 
activity of PFIs using three in vitro methods. 
Considering the current large and increasing 
production volume of telomerization­based 
PFCs, more extensive studies should be con­
ducted on the environmental distribution and 
toxicological effects of PFIs.
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